Humain Ventures is an Austin venture firm that backs founders building the future of therapeutics, prevention and human health, on the view that AI is turning biology into an engineering discipline. It runs a small, high-conviction portfolio and offers deep technical underwriting and hands-on help at company formation, from technical diligence and roadmaps to research and clinical strategy. It is led by Linea Avey, co-founder of 23andMe, and Aneil Mallavarapu, a mathematical biologist and five-time founder, with Michael Staton, who grew Learn Capital from $40M to $1.2B in assets under management. Its portfolio includes Unnatural Products, Chroma, NextSense, Radicle Science, Profile Health, Metabologic, Trace Health, Impulse Labs and Cognitive Scientific.